ARCHIVED: NOT AVAILABLE FOR CREDIT
Recent Updates in Oral and Oropharyngeal Cancer

 

This presentation provides an in depth discussion of current prognosis and staging criteria for oral cavity tumors and oropharyngeal tumors, specifically focusing on how HPV infection status, depth of invasion, and extranodal extension may alter the staging of these tumors and the subsequent treatment. The presentation also lists common treatment options for oral cavity cancer and oropharyngeal tumors, covering robotic surgical techniques, chemo and radiation therapies, and the potential benefits of immunotherapy.

Originally presented on February 12, 2020, in Park City, Utah.

Lecture Presenter

Luke O. Buchmann, MD

Luke O. Buchmann, MD

Associate Professor of Surgery
University of Utah School of Medicine

Dr. Buchmann joined the Division of Otolaryngology – Head & Neck Surgery at the University of Utah in 2008. He completed his residency at the University of Kansas, and a fellowship in Head & Neck Surgery and Microvascular Reconstruction at the Medical University of South Carolina. Dr. Buchmann has published in numerous medical journals and serves on a national committee related to head and neck cancer. Dr. Buchmann's clinical practice involves the diagnosis and surgical management of head and neck neoplasms including those of the upper aerodigestive tract, salivary glands, thyroid and the neck. He has additional expertise in microvascular reconstruction following head and neck cancer surgery. Research interests include evaluating functional outcomes following head and neck cancer surgery including swallowing, quality of life outcomes, and the evaluation of patient levels of psychological distress surrounding their cancer diagnosis.

Objectives

After this presentation, participants will be able to:

  • Discuss role of sentinel lymph node biopsy (SNLBX) in oral cavity cancer
  • Recognize the importance of depth of invasion (DOI) in new staging system
  • Recognize the importance of extranodal extension (ENE) in the new staging system
  • Discuss the importance of HPV status in oropharyngeal cancer staging
  • Recognize the drastic difference in overall stage in HPV (+) tumors
  • Discuss different treatment options for oropharyngeal cancer

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories